Plasma centres agreement signed in May 2007

Grifols obtains USD 10.7 million loan to fund the purchase of 4 plasma centres in the United States

- The funding issued by COFIDES (Spanish Development Finance Corporation) for a period of 9 years will be provided in US dollars, up to a limit of 8 million euros.

- The commercial loan will be used to part-finance the purchase of 4 plasma centres in the United States, under the agreement signed in May 2007.

Barcelona, 29 July 2008: Grifols, the Spanish holding company which specializes in the hospital-pharmaceuticals sector and is one of the world's leading producers of plasma products, has obtained a commercial loan from COFIDES, the Spanish Development Finance Corporation, for the sum of 10.7 million dollars, repayable after 9 years.

The money will be provided in dollars up to a value of 8 million euros, and will be used to part-finance the May 2007 purchase of four plasma collection centres in the United States. The rest of the funding for this purchase comes from the company's own resources. No repayments are due on the loan for the first two years of the term, after which it will be repaid in 14 equal six-monthly instalments.

COFIDES' decision to issue this loan reflects the group's positive financial position, and is clear evidence of the trust and support which COFIDES, a semi-public entity, has in Grifols. COFIDES, through its Overseas Investment Fund (FIEX), funds private projects in which there is a Spanish interest and which, on the basis of criteria of profitability, are judged likely to contribute to the internationalization of the Spanish economy.

The purchase of four plasmapheresis centres in the United States will give Grifols access to 150,000 additional litres for fractionation and conversion to plasma products. The incorporation of these centres into the group means that Grifols now has 79 plasma collection centres in the United States. However, Grifols plans to continue to increase the number of litres of plasma it has access to, both by acquiring new centres and by extending existing ones.
From a financial perspective, the details of the loan are as follows:

- **Total amount provided in dollars**: 10.7 million dollars (USD)
- **Maximum amount issued**: 8 million euros.
- **Term**: 9 years
- **Repayment**: No payments required for two years, then 14 equal six-monthly repayments.

### About COFIDES

COFIDES (the Spanish Development Finance Corporation) is a limited, mixed-capital (public and private) company created in 1988, whose purpose is to provide financial support for viable private projects in both emerging and developed countries in which there is a Spanish interest. These projects must meet profitability criteria, and contribute to the development of these countries and to the internationalisation of the Spanish economy and of Spanish companies.

In order to achieve this, in addition to its own funds, COFIDES also manages two state funds, FIEX and FONPYME. The corporation has a proven capacity to mobilize resources from other sources, and draws on a team of highly qualified professionals and the support of its shareholders.

In 2006, Spain’s Trade Department decided to expand the geographical remit of the FIEX and FONPYME Funds, extending them to developed countries and, in particular, to those which have an Integrated Market Development Plan: currently the United States, Japan and South Korea.

The corporate equity of COFIDES comes from leading bodies, including the Spanish Institute of Foreign Trade (ICEX), the Official Credit Institute (ICO), the National Corporation for Innovation (ENISA), Banco Bilbao Vizcaya Argentaria (BBVA), Banco Santander Central Hispano (Santander) and Banco de Sabadell.

Between them the three public entities - ICEX, ICO and ENISA - account for 61% of the equity of COFIDES. Since 2001 COFIDES has been given a rating of A+/Stable/A-1 by Standard & Poors.

### About Grifols

Grifols is a holding company specialized in the pharmaceutical-hospital sector and is present in more than 90 countries. Since May 2006, it has been quoted on the Spanish Stock Market, and forms part of the Ibex-35 Spanish index of medium capitalized companies. It is the leading European company in plasma derivatives and the fourth largest producer in the world. In coming years, Grifols will strengthen its leading position within the industry as a vertically integrated company, thanks both to investments which have already been made and a programme of investments for the period 2008 to 2012, worth a total of 400 million euros. In terms of raw materials, Grifols can rely on the supply of plasma from 77 plasmapheresis centres in the United States, while the fractionation capacity of its manufacturing facilities in Barcelona (Spain) and Los Angeles (United States) allow it to respond to the growing demand in the market. However, the company is not resting on its laurels and has implemented an ambitious investment plan which will deliver sustained increases over the next 8 to 10 years.